Larotrectinib for tumors with extra NTRK gene copies
Part of Cancer clinical trials.
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 16 years old
- Your tumor tests positive for NTRK1/2/3 gene amplification (minimum threshold: 7 copies) on an approved lab test
- Your cancer is advanced (locally advanced) or has spread (metastatic), and you’ve had standard treatment or can’t tolerate it
- You need at least one measurable tumor spot that can be followed on scans
- You must have usable stored tumor tissue, or be able to safely get a new biopsy
- Your organs must work well enough for treatment (blood tests and kidney/liver numbers must meet limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Hear when a new Locally Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.